MREOMereo BioPharma Group plc

Nasdaq mereobiopharma.com


$ 3.64 $ 0.04 (1.11 %)    

Friday, 05-Jul-2024 15:59:50 EDT
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 3.63
$ 3.55
$ 3.57 x 100
$ 0.00 x 0
$ 3.53 - $ 3.65
$ 1.07 - $ 4.50
701,514
na
2.54B
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 leerink-partners-maintains-outperform-on-mereo-biopharma-group-raises-price-target-to-8

Leerink Partners analyst Joseph Schwartz maintains Mereo BioPharma Group (NASDAQ:MREO) with a Outperform and raises the pric...

 baird-initiates-coverage-on-mereo-biopharma-group-with-outperform-rating-announces-price-target-of-8

Baird analyst Jack Allen initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Outperform rating and announces P...

 cantor-fitzgerald-reiterates-overweight-on-mereo-biopharma-group-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...

 needham-maintains-buy-on-mereo-biopharma-group-raises-price-target-to-7

Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and raises the price target from $6 to $7.

Core News & Articles

As of a May 24, 2024 data cut-off date, treatment with setrusumab (UX143) continued to significantly reduce incidence of fractu...

 cantor-fitzgerald-reiterates-overweight-on-mereo-biopharma-group-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...

 needham-reiterates-buy-on-mereo-biopharma-group-maintains-6-price-target

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.

 mereo-biopharma-group-q1-2024-adj-eps-001

Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate ...

 needham-reiterates-buy-on-mereo-biopharma-group-maintains-6-price-target

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.

 cantor-fitzgerald-reiterates-overweight-on-mereo-biopharma-group-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...

 needham-maintains-buy-on-mereo-biopharma-group-raises-price-target-to-6

Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and raises the price target from $5 to $6.

 mereo-biopharma-group-fy-eps-004-up-from-007-yoy-sales-1000m

Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.04) per share. This is a 42.86 percent increase over losse...